nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.0953	0.132	CbGbCtD
Tapentadol—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0328	0.0453	CbGbCtD
Tapentadol—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0308	0.0426	CbGbCtD
Tapentadol—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0279	0.0385	CbGbCtD
Tapentadol—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0279	0.0385	CbGbCtD
Tapentadol—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0272	0.0377	CbGbCtD
Tapentadol—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0256	0.0354	CbGbCtD
Tapentadol—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0256	0.0354	CbGbCtD
Tapentadol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0249	0.0345	CbGbCtD
Tapentadol—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0241	0.0333	CbGbCtD
Tapentadol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0234	0.0324	CbGbCtD
Tapentadol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0234	0.0324	CbGbCtD
Tapentadol—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0233	0.0323	CbGbCtD
Tapentadol—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0232	0.032	CbGbCtD
Tapentadol—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0232	0.032	CbGbCtD
Tapentadol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0212	0.0293	CbGbCtD
Tapentadol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0212	0.0293	CbGbCtD
Tapentadol—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0211	0.0292	CbGbCtD
Tapentadol—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0211	0.0292	CbGbCtD
Tapentadol—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0202	0.028	CbGbCtD
Tapentadol—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.02	0.0277	CbGbCtD
Tapentadol—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0194	0.0268	CbGbCtD
Tapentadol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0183	0.0253	CbGbCtD
Tapentadol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0178	0.0246	CbGbCtD
Tapentadol—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0176	0.0243	CbGbCtD
Tapentadol—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0176	0.0243	CbGbCtD
Tapentadol—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0168	0.0233	CbGbCtD
Tapentadol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0222	CbGbCtD
Tapentadol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0161	0.0222	CbGbCtD
Tapentadol—HTR3A—nerve—acquired immunodeficiency syndrome	0.00326	0.08	CbGeAlD
Tapentadol—OPRM1—nerve—acquired immunodeficiency syndrome	0.00299	0.0734	CbGeAlD
Tapentadol—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00219	0.0537	CbGeAlD
Tapentadol—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00188	0.0462	CbGeAlD
Tapentadol—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00161	0.0396	CbGeAlD
Tapentadol—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00156	0.0382	CbGeAlD
Tapentadol—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.0013	0.0319	CbGeAlD
Tapentadol—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00121	0.0297	CbGeAlD
Tapentadol—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000987	0.0242	CbGeAlD
Tapentadol—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00095	0.0233	CbGeAlD
Tapentadol—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000949	0.0233	CbGeAlD
Tapentadol—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000946	0.0232	CbGeAlD
Tapentadol—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000911	0.0223	CbGeAlD
Tapentadol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000908	0.0222	CbGeAlD
Tapentadol—HTR3A—blood—acquired immunodeficiency syndrome	0.000905	0.0222	CbGeAlD
Tapentadol—OPRM1—blood—acquired immunodeficiency syndrome	0.000829	0.0203	CbGeAlD
Tapentadol—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000799	0.0196	CbGeAlD
Tapentadol—HTR3A—lung—acquired immunodeficiency syndrome	0.000793	0.0194	CbGeAlD
Tapentadol—OPRD1—brain—acquired immunodeficiency syndrome	0.000755	0.0185	CbGeAlD
Tapentadol—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000734	0.018	CbGeAlD
Tapentadol—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000724	0.0177	CbGeAlD
Tapentadol—OPRK1—brain—acquired immunodeficiency syndrome	0.000723	0.0177	CbGeAlD
Tapentadol—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000707	0.0173	CbGeAlD
Tapentadol—SLC6A4—blood—acquired immunodeficiency syndrome	0.00069	0.0169	CbGeAlD
Tapentadol—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000673	0.0165	CbGeAlD
Tapentadol—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000665	0.0163	CbGeAlD
Tapentadol—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000648	0.0159	CbGeAlD
Tapentadol—SLC6A4—lung—acquired immunodeficiency syndrome	0.000605	0.0148	CbGeAlD
Tapentadol—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.0006	0.0147	CbGeAlD
Tapentadol—CYP2C19—blood—acquired immunodeficiency syndrome	0.000572	0.014	CbGeAlD
Tapentadol—HTR3A—brain—acquired immunodeficiency syndrome	0.000561	0.0138	CbGeAlD
Tapentadol—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.00056	0.0137	CbGeAlD
Tapentadol—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000539	0.0132	CbGeAlD
Tapentadol—SLC6A2—lung—acquired immunodeficiency syndrome	0.000532	0.013	CbGeAlD
Tapentadol—CYP2C19—vagina—acquired immunodeficiency syndrome	0.00053	0.013	CbGeAlD
Tapentadol—OPRM1—brain—acquired immunodeficiency syndrome	0.000515	0.0126	CbGeAlD
Tapentadol—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000493	0.0121	CbGeAlD
Tapentadol—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000475	0.0116	CbGeAlD
Tapentadol—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000465	0.0114	CbGeAlD
Tapentadol—CYP2C9—blood—acquired immunodeficiency syndrome	0.000443	0.0109	CbGeAlD
Tapentadol—SLC6A4—brain—acquired immunodeficiency syndrome	0.000428	0.0105	CbGeAlD
Tapentadol—SLC6A2—brain—acquired immunodeficiency syndrome	0.000377	0.00924	CbGeAlD
Tapentadol—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000364	0.00893	CbGeAlD
Tapentadol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000349	0.00856	CbGeAlD
Tapentadol—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000341	0.0144	CbGpPWpGaD
Tapentadol—CYP2D6—blood—acquired immunodeficiency syndrome	0.000332	0.00815	CbGeAlD
Tapentadol—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000321	0.0135	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000318	0.0134	CbGpPWpGaD
Tapentadol—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000299	0.0126	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000287	0.0121	CbGpPWpGaD
Tapentadol—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000281	0.0119	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000279	0.0118	CbGpPWpGaD
Tapentadol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.00027	0.00662	CbGeAlD
Tapentadol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00026	0.00637	CbGeAlD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00026	0.011	CbGpPWpGaD
Tapentadol—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000253	0.0107	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000252	0.0106	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000242	0.0102	CbGpPWpGaD
Tapentadol—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000241	0.00113	CcSEcCtD
Tapentadol—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00024	0.00113	CcSEcCtD
Tapentadol—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.00113	CcSEcCtD
Tapentadol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.00113	CcSEcCtD
Tapentadol—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000239	0.00113	CcSEcCtD
Tapentadol—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000239	0.00113	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000239	0.00113	CcSEcCtD
Tapentadol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000238	0.00112	CcSEcCtD
Tapentadol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000238	0.00112	CcSEcCtD
Tapentadol—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.00112	CcSEcCtD
Tapentadol—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.00112	CcSEcCtD
Tapentadol—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000238	0.01	CbGpPWpGaD
Tapentadol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000238	0.00112	CcSEcCtD
Tapentadol—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.00112	CcSEcCtD
Tapentadol—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000236	0.00111	CcSEcCtD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000236	0.00994	CbGpPWpGaD
Tapentadol—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.0011	CcSEcCtD
Tapentadol—Headache—Didanosine—acquired immunodeficiency syndrome	0.000234	0.0011	CcSEcCtD
Tapentadol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000234	0.0011	CcSEcCtD
Tapentadol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000234	0.0011	CcSEcCtD
Tapentadol—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.0011	CcSEcCtD
Tapentadol—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000233	0.0011	CcSEcCtD
Tapentadol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000233	0.0011	CcSEcCtD
Tapentadol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000233	0.0011	CcSEcCtD
Tapentadol—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000233	0.00109	CcSEcCtD
Tapentadol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.00109	CcSEcCtD
Tapentadol—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.00109	CcSEcCtD
Tapentadol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000232	0.00109	CcSEcCtD
Tapentadol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.00109	CcSEcCtD
Tapentadol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000231	0.00109	CcSEcCtD
Tapentadol—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.00109	CcSEcCtD
Tapentadol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000231	0.00108	CcSEcCtD
Tapentadol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00023	0.00108	CcSEcCtD
Tapentadol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00023	0.00108	CcSEcCtD
Tapentadol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00023	0.00108	CcSEcCtD
Tapentadol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.00108	CcSEcCtD
Tapentadol—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.00108	CcSEcCtD
Tapentadol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000228	0.00107	CcSEcCtD
Tapentadol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.00107	CcSEcCtD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000228	0.00961	CbGpPWpGaD
Tapentadol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000228	0.00107	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.00107	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000227	0.00107	CcSEcCtD
Tapentadol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000226	0.00107	CcSEcCtD
Tapentadol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000226	0.00107	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.00106	CcSEcCtD
Tapentadol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.00106	CcSEcCtD
Tapentadol—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.00106	CcSEcCtD
Tapentadol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000225	0.00106	CcSEcCtD
Tapentadol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.00106	CcSEcCtD
Tapentadol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000224	0.00106	CcSEcCtD
Tapentadol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000224	0.00106	CcSEcCtD
Tapentadol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.00105	CcSEcCtD
Tapentadol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000223	0.00105	CcSEcCtD
Tapentadol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000223	0.00105	CcSEcCtD
Tapentadol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000222	0.00105	CcSEcCtD
Tapentadol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000222	0.00105	CcSEcCtD
Tapentadol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.00104	CcSEcCtD
Tapentadol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000222	0.00104	CcSEcCtD
Tapentadol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.00104	CcSEcCtD
Tapentadol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.00104	CcSEcCtD
Tapentadol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000221	0.00104	CcSEcCtD
Tapentadol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000221	0.00104	CcSEcCtD
Tapentadol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.00104	CcSEcCtD
Tapentadol—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00022	0.00928	CbGpPWpGaD
Tapentadol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.00103	CcSEcCtD
Tapentadol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.00103	CcSEcCtD
Tapentadol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000219	0.00103	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.00103	CcSEcCtD
Tapentadol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.00103	CcSEcCtD
Tapentadol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.00102	CcSEcCtD
Tapentadol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000216	0.00102	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.00102	CcSEcCtD
Tapentadol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.00102	CcSEcCtD
Tapentadol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000216	0.00101	CcSEcCtD
Tapentadol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000216	0.00101	CcSEcCtD
Tapentadol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.00101	CcSEcCtD
Tapentadol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000216	0.00101	CcSEcCtD
Tapentadol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000215	0.00101	CcSEcCtD
Tapentadol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000215	0.00101	CcSEcCtD
Tapentadol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000215	0.00101	CcSEcCtD
Tapentadol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.00101	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.00101	CcSEcCtD
Tapentadol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.00101	CcSEcCtD
Tapentadol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000214	0.00101	CcSEcCtD
Tapentadol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.00101	CcSEcCtD
Tapentadol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.001	CcSEcCtD
Tapentadol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.001	CcSEcCtD
Tapentadol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.001	CcSEcCtD
Tapentadol—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000213	0.00898	CbGpPWpGaD
Tapentadol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000212	0.000999	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000212	0.00896	CbGpPWpGaD
Tapentadol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000212	0.000998	CcSEcCtD
Tapentadol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000212	0.000998	CcSEcCtD
Tapentadol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000212	0.000997	CcSEcCtD
Tapentadol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000212	0.000996	CcSEcCtD
Tapentadol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000212	0.000996	CcSEcCtD
Tapentadol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.000994	CcSEcCtD
Tapentadol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000211	0.000993	CcSEcCtD
Tapentadol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000211	0.000992	CcSEcCtD
Tapentadol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000989	CcSEcCtD
Tapentadol—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000988	CcSEcCtD
Tapentadol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000986	CcSEcCtD
Tapentadol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000983	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.000983	CcSEcCtD
Tapentadol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000209	0.000982	CcSEcCtD
Tapentadol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000978	CcSEcCtD
Tapentadol—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000207	0.00876	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000207	0.00876	CbGpPWpGaD
Tapentadol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000207	0.000975	CcSEcCtD
Tapentadol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000207	0.000975	CcSEcCtD
Tapentadol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000207	0.000972	CcSEcCtD
Tapentadol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.000971	CcSEcCtD
Tapentadol—CYP2D6—brain—acquired immunodeficiency syndrome	0.000206	0.00506	CbGeAlD
Tapentadol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000968	CcSEcCtD
Tapentadol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000205	0.000967	CcSEcCtD
Tapentadol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000205	0.000966	CcSEcCtD
Tapentadol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000966	CcSEcCtD
Tapentadol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000205	0.000965	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000205	0.000964	CcSEcCtD
Tapentadol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000205	0.000964	CcSEcCtD
Tapentadol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000205	0.000963	CcSEcCtD
Tapentadol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000205	0.000963	CcSEcCtD
Tapentadol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000204	0.000962	CcSEcCtD
Tapentadol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000204	0.000961	CcSEcCtD
Tapentadol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000204	0.000961	CcSEcCtD
Tapentadol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000204	0.000958	CcSEcCtD
Tapentadol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000204	0.000958	CcSEcCtD
Tapentadol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.000956	CcSEcCtD
Tapentadol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000203	0.000955	CcSEcCtD
Tapentadol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000203	0.000953	CcSEcCtD
Tapentadol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000202	0.00095	CcSEcCtD
Tapentadol—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000202	0.00852	CbGpPWpGaD
Tapentadol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000202	0.000949	CcSEcCtD
Tapentadol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.000949	CcSEcCtD
Tapentadol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.000949	CcSEcCtD
Tapentadol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000201	0.000943	CcSEcCtD
Tapentadol—Infection—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000942	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000941	CcSEcCtD
Tapentadol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.0002	0.00094	CcSEcCtD
Tapentadol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.0002	0.00094	CcSEcCtD
Tapentadol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.000934	CcSEcCtD
Tapentadol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000933	CcSEcCtD
Tapentadol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.00093	CcSEcCtD
Tapentadol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.000929	CcSEcCtD
Tapentadol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.000928	CcSEcCtD
Tapentadol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.000928	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000197	0.00831	CbGpPWpGaD
Tapentadol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.000921	CcSEcCtD
Tapentadol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.000921	CcSEcCtD
Tapentadol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000196	0.000921	CcSEcCtD
Tapentadol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.000918	CcSEcCtD
Tapentadol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000917	CcSEcCtD
Tapentadol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000194	0.000911	CcSEcCtD
Tapentadol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000193	0.00091	CcSEcCtD
Tapentadol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000909	CcSEcCtD
Tapentadol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000193	0.000909	CcSEcCtD
Tapentadol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000193	0.000908	CcSEcCtD
Tapentadol—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000193	0.00813	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000193	0.00813	CbGpPWpGaD
Tapentadol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000906	CcSEcCtD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000192	0.00812	CbGpPWpGaD
Tapentadol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000899	CcSEcCtD
Tapentadol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.000898	CcSEcCtD
Tapentadol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00019	0.000895	CcSEcCtD
Tapentadol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.000893	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00019	0.000892	CcSEcCtD
Tapentadol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.000891	CcSEcCtD
Tapentadol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.000887	CcSEcCtD
Tapentadol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000188	0.000887	CcSEcCtD
Tapentadol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.000886	CcSEcCtD
Tapentadol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.000886	CcSEcCtD
Tapentadol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.000884	CcSEcCtD
Tapentadol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000188	0.000883	CcSEcCtD
Tapentadol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000187	0.000879	CcSEcCtD
Tapentadol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.000875	CcSEcCtD
Tapentadol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000186	0.000874	CcSEcCtD
Tapentadol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.000864	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000864	CcSEcCtD
Tapentadol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000183	0.00086	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000858	CcSEcCtD
Tapentadol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.000858	CcSEcCtD
Tapentadol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000857	CcSEcCtD
Tapentadol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.000852	CcSEcCtD
Tapentadol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.000851	CcSEcCtD
Tapentadol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000181	0.00085	CcSEcCtD
Tapentadol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.000846	CcSEcCtD
Tapentadol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00018	0.000846	CcSEcCtD
Tapentadol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00018	0.000845	CcSEcCtD
Tapentadol—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000179	0.00757	CbGpPWpGaD
Tapentadol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.000843	CcSEcCtD
Tapentadol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000178	0.000838	CcSEcCtD
Tapentadol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000178	0.000838	CcSEcCtD
Tapentadol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000178	0.000837	CcSEcCtD
Tapentadol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000835	CcSEcCtD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000177	0.00749	CbGpPWpGaD
Tapentadol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000177	0.000832	CcSEcCtD
Tapentadol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000176	0.000826	CcSEcCtD
Tapentadol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.000825	CcSEcCtD
Tapentadol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000175	0.000823	CcSEcCtD
Tapentadol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000821	CcSEcCtD
Tapentadol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.000819	CcSEcCtD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000174	0.00735	CbGpPWpGaD
Tapentadol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000819	CcSEcCtD
Tapentadol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000818	CcSEcCtD
Tapentadol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000174	0.000817	CcSEcCtD
Tapentadol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000172	0.000811	CcSEcCtD
Tapentadol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.000802	CcSEcCtD
Tapentadol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00017	0.000799	CcSEcCtD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000169	0.00713	CbGpPWpGaD
Tapentadol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000168	0.00079	CcSEcCtD
Tapentadol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00079	CcSEcCtD
Tapentadol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000168	0.000789	CcSEcCtD
Tapentadol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000167	0.000786	CcSEcCtD
Tapentadol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000782	CcSEcCtD
Tapentadol—SLC6A4—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.000166	0.00701	CbGpPWpGaD
Tapentadol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000166	0.000779	CcSEcCtD
Tapentadol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000165	0.000778	CcSEcCtD
Tapentadol—Headache—Indinavir—acquired immunodeficiency syndrome	0.000165	0.000774	CcSEcCtD
Tapentadol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000164	0.000772	CcSEcCtD
Tapentadol—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000163	0.00687	CbGpPWpGaD
Tapentadol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000162	0.000764	CcSEcCtD
Tapentadol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000162	0.000761	CcSEcCtD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00016	0.00677	CbGpPWpGaD
Tapentadol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000754	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000158	0.00669	CbGpPWpGaD
Tapentadol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000158	0.000742	CcSEcCtD
Tapentadol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000741	CcSEcCtD
Tapentadol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.000739	CcSEcCtD
Tapentadol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000156	0.000736	CcSEcCtD
Tapentadol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000156	0.000735	CcSEcCtD
Tapentadol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000156	0.000734	CcSEcCtD
Tapentadol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000733	CcSEcCtD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000155	0.00656	CbGpPWpGaD
Tapentadol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000155	0.000731	CcSEcCtD
Tapentadol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000155	0.000731	CcSEcCtD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000153	0.00644	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000152	0.00643	CbGpPWpGaD
Tapentadol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000713	CcSEcCtD
Tapentadol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000151	0.00071	CcSEcCtD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000151	0.00636	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000151	0.00636	CbGpPWpGaD
Tapentadol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00015	0.000707	CcSEcCtD
Tapentadol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00015	0.000704	CcSEcCtD
Tapentadol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00015	0.000704	CcSEcCtD
Tapentadol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00015	0.000703	CcSEcCtD
Tapentadol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000149	0.0007	CcSEcCtD
Tapentadol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000699	CcSEcCtD
Tapentadol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000147	0.000694	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000147	0.00619	CbGpPWpGaD
Tapentadol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000145	0.000683	CcSEcCtD
Tapentadol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000681	CcSEcCtD
Tapentadol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000145	0.00068	CcSEcCtD
Tapentadol—SLC6A2—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.000143	0.00603	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000143	0.00602	CbGpPWpGaD
Tapentadol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000143	0.000671	CcSEcCtD
Tapentadol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000141	0.000664	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000141	0.00594	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000141	0.00594	CbGpPWpGaD
Tapentadol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000658	CcSEcCtD
Tapentadol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00014	0.000657	CcSEcCtD
Tapentadol—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000139	0.00588	CbGpPWpGaD
Tapentadol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000651	CcSEcCtD
Tapentadol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000651	CcSEcCtD
Tapentadol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000649	CcSEcCtD
Tapentadol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000647	CcSEcCtD
Tapentadol—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000135	0.00571	CbGpPWpGaD
Tapentadol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000632	CcSEcCtD
Tapentadol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.000627	CcSEcCtD
Tapentadol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000133	0.000627	CcSEcCtD
Tapentadol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000133	0.000626	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000133	0.0056	CbGpPWpGaD
Tapentadol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000623	CcSEcCtD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000132	0.00558	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000132	0.00558	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000131	0.00555	CbGpPWpGaD
Tapentadol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000614	CcSEcCtD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000129	0.00545	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000129	0.00543	CbGpPWpGaD
Tapentadol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.000603	CcSEcCtD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000127	0.00537	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000127	0.00537	CbGpPWpGaD
Tapentadol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000598	CcSEcCtD
Tapentadol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000598	CcSEcCtD
Tapentadol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000594	CcSEcCtD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000126	0.0053	CbGpPWpGaD
Tapentadol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000591	CcSEcCtD
Tapentadol—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000124	0.00524	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000123	0.00519	CbGpPWpGaD
Tapentadol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000563	CcSEcCtD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000119	0.00502	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000119	0.00502	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000119	0.00501	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000118	0.00498	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000116	0.00491	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000115	0.00484	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000113	0.00478	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000112	0.00472	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000112	0.00472	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000112	0.00471	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000112	0.00471	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00011	0.00465	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000109	0.0046	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000109	0.00459	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000108	0.00454	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000104	0.0044	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00437	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000103	0.00436	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000103	0.00433	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000101	0.00427	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000101	0.00427	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000101	0.00425	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.0001	0.00423	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.83e-05	0.00415	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.68e-05	0.00408	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.43e-05	0.00398	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.43e-05	0.00398	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.43e-05	0.00398	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.3e-05	0.00393	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.2e-05	0.00388	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.06e-05	0.00383	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.06e-05	0.00382	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.87e-05	0.00374	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.87e-05	0.00374	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.82e-05	0.00372	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.75e-05	0.00369	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	8.74e-05	0.00369	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.72e-05	0.00368	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	8.5e-05	0.00359	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.49e-05	0.00358	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.19e-05	0.00346	CbGpPWpGaD
Tapentadol—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.09e-05	0.00342	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.97e-05	0.00337	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.94e-05	0.00335	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.7e-05	0.00325	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.7e-05	0.00325	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.69e-05	0.00325	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	7.66e-05	0.00323	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.64e-05	0.00323	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.52e-05	0.00318	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.5e-05	0.00316	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.5e-05	0.00316	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.49e-05	0.00316	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.34e-05	0.0031	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TAT—acquired immunodeficiency syndrome	7.29e-05	0.00308	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.18e-05	0.00303	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.17e-05	0.00303	CbGpPWpGaD
Tapentadol—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.09e-05	0.00299	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.93e-05	0.00293	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.8e-05	0.00287	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.75e-05	0.00285	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.75e-05	0.00285	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.75e-05	0.00285	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.71e-05	0.00283	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.6e-05	0.00279	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.46e-05	0.00273	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.43e-05	0.00272	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AGPS—acquired immunodeficiency syndrome	6.2e-05	0.00262	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.08e-05	0.00257	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.07e-05	0.00256	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	6.05e-05	0.00255	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6e-05	0.00253	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.97e-05	0.00252	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TAT—acquired immunodeficiency syndrome	5.93e-05	0.0025	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.86e-05	0.00247	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.71e-05	0.00241	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.71e-05	0.00241	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.7e-05	0.00241	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.58e-05	0.00235	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.44e-05	0.0023	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.32e-05	0.00224	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.28e-05	0.00223	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.14e-05	0.00217	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.14e-05	0.00217	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.04e-05	0.00213	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AGPS—acquired immunodeficiency syndrome	5.04e-05	0.00213	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.85e-05	0.00205	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.73e-05	0.002	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.68e-05	0.00197	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.65e-05	0.00196	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.63e-05	0.00195	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.63e-05	0.00195	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	4.52e-05	0.00191	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.44e-05	0.00188	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.44e-05	0.00188	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.35e-05	0.00184	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.35e-05	0.00184	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.34e-05	0.00183	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.28e-05	0.00181	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.2e-05	0.00177	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.08e-05	0.00172	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.06e-05	0.00171	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.02e-05	0.0017	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.95e-05	0.00167	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.95e-05	0.00167	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.91e-05	0.00165	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.9e-05	0.00165	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.9e-05	0.00165	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.82e-05	0.00161	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.82e-05	0.00161	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.77e-05	0.00159	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.69e-05	0.00156	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.52e-05	0.00149	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.47e-05	0.00146	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.47e-05	0.00146	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.44e-05	0.00145	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.43e-05	0.00145	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.31e-05	0.0014	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.29e-05	0.00139	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.29e-05	0.00139	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.26e-05	0.00138	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.23e-05	0.00136	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.23e-05	0.00136	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.12e-05	0.00132	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.08e-05	0.0013	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.01e-05	0.00127	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.98e-05	0.00126	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.98e-05	0.00126	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.96e-05	0.00125	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.93e-05	0.00124	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.93e-05	0.00124	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.9e-05	0.00123	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.86e-05	0.00121	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	2.79e-05	0.00118	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.75e-05	0.00116	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.71e-05	0.00114	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.64e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.62e-05	0.0011	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.6e-05	0.0011	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.56e-05	0.00108	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.54e-05	0.00107	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.48e-05	0.00105	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.45e-05	0.00104	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.42e-05	0.00102	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.41e-05	0.00102	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.38e-05	0.001	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.37e-05	0.001	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.33e-05	0.000986	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.33e-05	0.000986	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.32e-05	0.00098	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.3e-05	0.00097	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.23e-05	0.000941	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.21e-05	0.000933	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.19e-05	0.000927	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.18e-05	0.00092	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.18e-05	0.000919	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.16e-05	0.000912	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.05e-05	0.000864	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.05e-05	0.000864	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.03e-05	0.000859	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.01e-05	0.000847	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.84e-05	0.000777	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.00075	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000739	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.73e-05	0.00073	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.73e-05	0.00073	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.72e-05	0.000728	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.000676	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000661	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.56e-05	0.000657	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000648	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.51e-05	0.000638	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000592	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000579	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.32e-05	0.000556	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.000547	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.28e-05	0.000539	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—acquired immunodeficiency syndrome	1.27e-05	0.000537	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.19e-05	0.000501	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.16e-05	0.00049	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.09e-05	0.00046	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	1.03e-05	0.000436	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.94e-06	0.00042	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.25e-06	0.00039	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.2e-06	0.000388	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.11e-06	0.000342	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.07e-06	0.000341	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.85e-06	0.000289	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.82e-06	0.000288	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.43e-06	0.000229	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	4.86e-06	0.000205	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.77e-06	0.000201	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.47e-06	0.000189	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	4.43e-06	0.000187	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.03e-06	0.00017	CbGpPWpGaD
